MEDICAL CANNABIS GUIDE

Glaucoma & Medical Cannabis

Glaucoma is one of the original qualifying conditions for medical cannabis, with research dating to the 1970s. THC lowers intraocular pressure (IOP) — the primary driver of glaucom...

CANNABINOIDS
THC primary
EVIDENCE LEVEL
Moderate Evidence
MEDICAL ACCESS
30+ States
APPROVED SINCE
1978 (Research IND)

How THC Reduces Eye Pressure

Medical cannabis for Glaucoma
Cannabis-based treatments are increasingly accessible for Glaucoma patients worldwide.

CB1 receptors are expressed in ocular tissues including the ciliary body, which produces aqueous humour. THC activation of these receptors reduces aqueous humour production and increases trabecular outflow, decreasing IOP. This mechanism was identified in the 1970s through research conducted under FDA-approved Investigational New Drug (IND) protocols. The challenge is that THC's IOP-lowering effect lasts only 3-4 hours, requiring dosing 6-8 times daily for continuous pressure control. Understanding THC's pharmacology helps patients and clinicians optimise dosing. Pain relief effects are also relevant as glaucoma can cause acute ocular pain.

Clinical Evidence & Research

Multiple studies from the 1970s-1990s established that smoked cannabis reduces IOP by 25-30% for 3-4 hours. However, a 2003 American Academy of Ophthalmology review noted that the dosing frequency required for 24-hour IOP control would result in constant intoxication, limiting practical utility. More recent research has focused on cannabinoid eye drops, which could deliver targeted IOP reduction without systemic effects. CBD alone paradoxically increases IOP transiently — an important finding for glaucoma patients using CBD-dominant products without THC. Israel and the Netherlands permit medical cannabis for glaucoma.

Access & Patient Requirements

Glaucoma is a qualifying condition in 30+ US medical cannabis states, making it one of the most widely accepted eye conditions. An ophthalmologist diagnosis and documented IOP measurements are typically required. California has included glaucoma since its programme inception. Colorado and New York both accept glaucoma. Most ophthalmologists are cautious about recommending cannabis as primary glaucoma therapy due to the dosing frequency limitation.

Recommended Cannabis Approaches for Glaucoma

For most glaucoma patients, cannabis is adjunctive therapy rather than primary IOP management. THC (via vaporisation or sublingual) can provide acute IOP relief during pressure spikes or complement prescription eye drops. Night-time dosing may be most practical as conventional IOP medications often have their lowest efficacy during sleep. Avoid CBD-only products for glaucoma, as CBD can transiently increase IOP. Monitor IOP with your ophthalmologist regularly if using cannabis as part of your glaucoma management. THC dosing guidelines should be discussed with your eye care specialist.

Research & Further Reading

Frequently Asked Questions

Does cannabis lower eye pressure?
Yes. THC reduces intraocular pressure by 25-30% for 3-4 hours through CB1 receptor activation in ocular tissues. This was established in multiple studies from the 1970s onwards. The limitation is that frequent dosing would be required for continuous 24-hour IOP control.
Is glaucoma a qualifying condition for medical cannabis?
Yes, in 30+ US medical cannabis states. Glaucoma is among the original qualifying conditions from the earliest state programmes. An ophthalmologist diagnosis and documented elevated IOP are typically required. California has included glaucoma since its 1996 programme inception.
Can CBD help glaucoma?
No. Contrary to expectations, CBD transiently increases intraocular pressure — the opposite of the desired effect for glaucoma management. Only THC consistently lowers IOP. Glaucoma patients should avoid CBD-only products and ensure their cannabis preparation contains meaningful THC levels.
Why don't eye doctors recommend cannabis for glaucoma?
Most ophthalmologists acknowledge cannabis lowers IOP but note the short duration (3-4 hours) requires dosing 6-8 times daily for continuous pressure control, resulting in constant intoxication. Modern prescription IOP medications (latanoprost, timolol) control pressure for 12-24 hours with one or two daily doses, making them more practical.
Is there a cannabis eye drop for glaucoma?
Cannabinoid eye drops are under active research and clinical development. They could theoretically deliver local IOP reduction without systemic psychoactive effects. No cannabis-based eye drop has received regulatory approval as of 2026, but several are in Phase II clinical trials. Conventional eye drops remain the current standard of care.

Related Medical Cannabis Guides